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Abstract
Background: In 2007, the Chinese Science Division of the State Administration of Traditional
Chinese Medicine(TCM) convened a special conference to discuss quality control for TCM clinical
research. Control and assurance standards were established to guarantee the quality of clinical
research. This paper provides practical guidelines for implementing strict and reproducible quality
control for acupuncture randomized controlled trials (RCTs).
Methods: A standard quality control program (QCP) was established to monitor the quality of
acupuncture trials. Case report forms were designed; qualified investigators, study personnel and
data management personnel were trained. Monitors, who were directly appointed by the project
leader, completed the quality control programs. They guaranteed data accuracy and prevented or
detected protocol violations. Clinical centers and clinicians were audited, the randomization
system of the centers was inspected, and the treatment processes were audited as well. In addition,
the case report forms were reviewed for completeness and internal consistency, the eligibility and
validity of the patients in the study was verified, and data was monitored for compliance and
accuracy.
Results and discussion: The monitors complete their reports and submit it to quality assurance
and the sponsors. Recommendations and suggestions are made for improving performance. By
holding regular meetings to discuss improvements in monitoring standards, the monitors can
improve quality and efficiency.
Conclusions: Supplementing and improving the existed guidelines for quality monitoring will
ensure that large multi-centre acupuncture clinical trials will be considered as valid and scientifically
stringent as pharmaceutical clinical trials. It will also develop academic excellence and further
promote the international recognition of acupuncture.
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Introduction
Acupuncture is a typical traditional medicine that has
been widely used in clinical practice for thousands of
years in China. Because of its multi-advantages, acupunc-
ture has been gradually obtained acceptance as an alterna-
tive or complementary treatment for health care in many
western countries. In 1997, at a Consensus Conference
sponsored by the National Institutes of Health, acupunc-
ture was recognized as an effective treatment for chronic
pain syndromes and for postoperative and chemotherapy-
induced nausea and vomiting. Acupuncture has also
received recognition as a beneficial adjunct for treating
drug addiction, stroke rehabilitation and asthma[1]. In
the UK, acupuncture is widely used in both private and
NHS practice. In surveys of the use of complementary
medicine, acupuncture is consistently cited among the
most commonly used[2].
At present, the systematic review of evidence-based medi-
cine (EBM) and large sample randomized controlled trial
(RCT) are considered as the most reliable evidence which
guides the clinical practice. The initial concept of EBM was
defined as the "conscientious, explicit and judicious use
of the available evidence in making decision about indi-
vidual patient care"[3]. Currently, the integration of best
external clinical evidence available from systematic
research with individual clinical expertise and patient
preferences is the standard in practice[4]. In assessing the
effectiveness of treatment modalities involving human
subjects, the RCT design is generally considered as the
gold standard method with the least spurious causality
and bias [5].
Recent years, many RCTs using acupuncture were carried
out in Germany, USA, England and other western coun-
tries [6-8]. In China, the multi-center acupuncture studies
with large sample of RCTs have generated a considerable
amount of attention. Both National Key Basic Research
Program (973 Program) and the "11th Five-Year Plan
National Key Technology R & D" were designed as the
multi-center randomized controlled trials, which were
supported financially by China's Ministry of Science and
Technology.
In order to complete multi-center acupuncture clinical tri-
als with high quality, the Science Division of the State
Administration of TCM of China convened a special con-
ference about quality control on clinical research of TCM
in 2007. The conference established a series of control and
assurance standards to guarantee the quality of clinical
research. We recognize the quality controls that already
existed were not adequate for acupuncture clinical trials.
The reporting quality of RCTs published in the five lead-
ing Chinese medical journals is low[9]. Based on the
STRICTA checklist, the assessment of RCTs published in
Chinese Acupuncture and Moxibustion indicates that the
methodological quality was lower than the international
standard, especially on acupuncturist's qualification,
adverse reaction, blind method, flow of participants in the
trial and follow-up, et al[10]. Poor reporting of RCTs give
more urgency to improve quality monitoring of multi-
center acupuncture clinical trials in China.
This paper provides practical guidelines for implementing
strict and reproducible quality control for acupuncture
RCTs. The clinical trials reported in this article are
financed by the "973program" and "11th Five-Year Plan"
from National Key Technology R & D program of China
respectively, and both programs are registered with their
own identifier (NCT00599586, NCT00608660) by Clini-
cal Trials.gov in the USA. These trials are performed
according to the principles of the Declaration of Helsinki
(Version Edinburgh 2000). And the trial protocols have
been approved by local institutional review board and
ethics committee. Chengdu University of TCM takes
charge of these studies. The first part of clinical research of
"973program" (Grant No.2006CB504501) has published
the initial results [11]. The second part of our project is
undergoing in China and its study protocol has published
in TRIALS [12].
Methods
The practice of quality monitoring of these acupuncture
trials focuses on making the standard quality control pro-
gram (QCP). This QCP includes the design of case report
form (CRF), the training of qualified investigators, study
personnel and data management. All of quality control
programs are completed by monitors who are directly
appointed by the project leader. The duty of these moni-
tors is to guarantee data accuracy and to prevent or detect
protocol violations such as enrollment of noneligible
patients or assignment of improper treatment and so on.
Therefore, the monitors should satisfy the following
requirements: (1) having medical background, mastering
the strict training of GCP standard, and having abundant
experience of clinical trials; (2) being familiar with proto-
col of the trial and standard operating procedures (SOPs);
(3) monitoring the whole procedures of data manage-
ment, including filling in the Case Report Forms(CRFs)
and electro-CRFs as well as modification error; (4) having
adequate time to do the monitoring work periodically
according to the QCP.
Preparation work on quality monitoring
Monitors should first understand and control the moni-
toring program. This scheme usually includes: (1) decid-
ing the number of monitors in each clinical center,
according to the number of centers; (2) planning the
supervision speed in terms of clinical trial progress; (3)
adjusting the inspection frequency based on the trial
schedule.Trials 2009, 10:123 http://www.trialsjournal.com/content/10/1/123
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At the same time, the monitors should draw up the mon-
itoring assessment forms (see Additional File 1) which are
developed from the GCP regulations, and these forms are
designed according to the characteristics of acupuncture
clinical trials. Questions are not rated per se; each assess-
ment question has one of the possible responses: yes, or
no, and some questions are provided with brief descrip-
tions as well.
Implementation is the core aspect of the monitoring pro-
cedure, which includes the following steps:(1) reading the
study summaries, feedback comments and on-the-spot
suggestions from each clinical center before the inspec-
tions;(2) maintaining a good communication with the
director of each centre, clinicians, patients and laboratory
examiners, to be informed of every concrete flow of pro-
cedure and the progress;(3)taking notes about the prob-
lems, flaws, and on-the-spot photos;(4)summarizing the
monitoring results and evaluate the integrity and credibil-
ity of clinical data collections.
The practice of quality monitoring
1. Audit the preparation work in every clinical center
We check every clinical center which participates in these
clinical trials to see how much they value the project and
check the use and management of clinical diagnosis
equipments, acupuncture appliances and the laboratory
examination instruments to see whether these instru-
ments are in line with the requirements of SOPs. Mean-
while, the monitors should examine if there is any change
to the clinical investigators, and if all of them are well
trained or have passed the exam on implementation
scheme which is organized by the sponsor.
2. Inspect the master degree of procedures
The clinicians play an important role and participate in
most of steps during the implementation of the studies.
Their duties are not exactly the same in each period of
trial, such as recruiting, enrolling, screening, randomized
allocation, treating patients and follow-up. Therefore, it is
indispensable to ensure that the clinicians grasp the pro-
cedures systematically.
(1) Inspecting the usage of center-randomization system
Monitors inspect the usage of center-randomization system
and ask if the clinicians have confirmed the case histories
and laboratory tests that meet inclusion criteria. They also
check whether the clinicians grasp the procedure of apply-
ing center-randomization and whether they can remember
the English alphabets, which represent specific divisions in
the feedback messages through telephone, mobile phone,
mobile-phone message, or website.
(2) Auditing the process of treatment
It is necessary to analyze the process of treatment and
operations. Firstly, monitors check whether the diagnosis,
disease stages and classifications conform to the inclusion
criterias. We use the patient's medical records, the corre-
sponding conclusions of laboratory examinations, as well
as the records of patients with symptoms, such as the
headache diaries of attack frequency, attack duration,
simultaneous phenomenon to determine the certainty of
basic information of illness.
Secondly, we inspect whether or not the course of the
treatment strictly corresponds to the randomized imple-
mentation of the corresponding treatment measures
including the selection and location of acupoints or non-
acupoints, acupuncture manipulation, the operation of
electro-acupuncture, SOPs adherence, etc. All procedures
should be recorded by taking pictures.
Thirdly, we pay special attention to the physicians' expla-
nations on whether we should follow the clinical research
requirements and the GCP regulation during our commu-
nication with the subjects. Due to the unique nature of
acupuncture operations, the double-blind cannot be
adopted between subjects and physicians. However, the
clinicians cannot assess the efficacy of treatment on sub-
jects to avoid misleading the patients, and therefore, cause
potential impact on the compliance and outcome meas-
urement. For example, patients are randomly divided and
may be acceptable to the treatment of non-acupoints or
acupoints. The clinicians should not imply which method
is better throughout the course of the treatment. The hint
will affect the clinical effects and bring interference to the
study results.
3. Reviewing sites' CRFs for completeness and internal 
consistency
In order to affirm the validity, integrity, and accuracy of
research documents, monitors have to look up all of the
CRFs one by one. This step is not only the focus of moni-
toring, but also a controversy issue. We have learned
about experiences from domestic and international coun-
terparts in the pharmaceutical clinical research [13-15].
(1) Verifying the patients' eligibility and validity
Monitors verify the informed consent of autograph, and
randomly call the patients with the contact phone
number provided on the CRF, so as to ensure the authen-
ticity of the subjects, and to check the diagnosis and the
main treatment experiences. At the same time, monitors
review the original medical histories and laboratory tests
(e.g. routine test of blood, urine and stool, electrocardio-
gram, liver function, and kidney function) in order to
affirm the patients eligibility.
(2) Data monitoring
Monitors ensure the data recording in CRFs are compliant
with the medical records and laboratory reports. In partic-Trials 2009, 10:123 http://www.trialsjournal.com/content/10/1/123
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ular, the monitors need to review records for key elements
and data validation. The following aspects are practiced:
1) We check the testing time, the contents of enrolling lab-
oratory tests, and the filling time in forms to guarantee the
timeliness and integrity. Additionally, we make sure that
the revision mistake must conform to the standard and
has the signature of superintendent. We also review
whether there is any alteration that cannot be explained
by reasonable causes or intentional revision in the scales
and the main indexes.
2) Some randomly selected subjects were asked on-the-
spot regarding their case histories, treatments and drug
combination in order to audit the facticity and complete-
ness of CRF documents. The monitors specifically inquire
treating histories including the information about the
drug usage before patients' enrollment and whether
patients combine the medication therapy during the
research or even take the unapproved concomitant ther-
apy in protocol. Moreover, if the patient took any drugs,
the clinicians should record the information in the CRF
form with the start-stops date. However, if the patients
took the medication that is not allowed, we will evaluate
the elimination if it is fit for the GCP principle. For
instance, if the migraine patients took the medicine, we
would ask the patients themselves and the doctors to
truthfully document the name, the dosage of medicine,
the time of taking the medicine, the time of pain relief and
the side effects of the medicine. Furthermore, if a patient
has taken prophylactic drugs to prevent migraine during
the treatment period, the patient will be told to drop out
according to the GCP and protocol.
3) We supervise assessment for adverse events. There are
some arguments on acupuncture-induced adverse events
in the international acupuncture academia at present, and
the domestic clinical trials of acupuncture on this issue
were not fully reported previously. Therefore, sponsors
and monitors pay special attention on the recording and
verification of safety monitoring and adverse events in
acupuncture studies. Adverse events are classified by the
State Food and Drug Administration (SFDA) of China
using two criteria in specific order: adverse event and seri-
ous adverse event. Serious adverse events refer to required
hospitalization, extended duration of hospitalization, dis-
ability, impact on the ability to work, life-threaten or
death, resulting in events such as congenital malforma-
tions in the process of clinical trials. Up to now, the mon-
itors have confirmed that there is no case of serious
adverse events in all of these trials. Any adverse events
must be recorded, including serious bleeding, hematoma,
fainting, serious pain and local infection. How to deal
with these events must be recorded as well. All of the
adverse events must be handled and followed up. Take a
case for example: a patient (random number:216) had
subcutaneous hematoma and ecchymosis at the point of
"Zusanli" (ST36) which appeared around one centimeter
in diameter after the needle was withdrew. The physician
gave local cold compress immediately, and advised the
patient to hot compress after 24 hours. The patient's
hematoma problem improved significantly the next day
and all the symptoms completely disappeared after two
weeks.
4) We audit the promptness and completeness of follow-
up. All the patients in these trials need to complete the
outcome measurements after treatment in 4 and 12
weeks, in order to assess and compare the long-term fol-
low-up results in different treatment group. But not every-
one has enough time to return visit to receive the scale
evaluation actually. As a result, monitors have to inspect
assessors to document whether or not the way of follow-
up, including by out-patient, telephone, email, and web-
cam. During the follow-up, Bell's palsy patients mostly
selected out-patient or webcam because they cannot judge
the function of facial muscle by themselves. On the con-
trary, migraine patients eagerly used telephone or email to
complete the scale evaluation.
(3) Verifying the description of subjects dropout and lost to follow-up
Monitors have accountability to know the quantities of
dropouts, suspension and lost to follow-up, and assess the
authenticity and comprehensiveness of reasons. We check
if the details of withdraw in CRFs have been recorded.
Generally speaking, the causes of withdraw commonly
have the following conditions: Firstly, the subjects are too
busy to complete the treatment course. Secondly, patients
return to home town and they cannot stick to the treat-
ment. Thirdly, patients violate advice and refuse to com-
ply with the protocol.
If these kinds of subjects constituted a large proportion,
doctors should arouse patients' initiative, improve the
attitude in clinics, and exhibit more concerns in order to
obtain patients' trust and cooperation, and strengthen
their compliance.
(4) Evaluating the conservation of materials
Each clinical center should keep the entire files well,
including patients' records, laboratory checking reports,
CRF forms regardless of their filing status, and other
essential documents. Monitors evaluate whether there is
omission or loss in relevant materials and reports.
Final report on quality monitoring
After assessing of on-site performance, monitors have to
accomplish the monitoring report. The report is submit-
ted to QA and the sponsors. All reports must be com-
pleted in handwriting. The monitors put forwardTrials 2009, 10:123 http://www.trialsjournal.com/content/10/1/123
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recommendations and suggestions to every cooperative
center. The contents of monitoring report should focus on
review of regulatory documents, acupuncture audit, rec-
ommendations for improving performance, and the recti-
fication on the previous monitors' recommendations. By
holding regular meetings to discuss improvements in
monitoring standards, the monitors can improve quality
and efficiency.
Summary and Conclusions
The National Basic Research Program (973 Program) and
the "11th Five-year Plan" National Key Technology R & D
program are the most important research program based
on clinical practice in China. Up to now, these projects are
respectively the largest clinical trial involved in the spe-
cific physiological effects of acupoints[13], and one of the
largest randomized controlled trials addressing the effec-
tiveness of acupuncture treatment, and the best acupunc-
ture treatment method for Bell's palsy[16] Monitoring
work in these multi-centre large sample acupuncture clin-
ical trials are as serious and scientific as pharmaceutical
clinical test, which is essential for data accuracy and
proper evaluation of study objectives in clinical trials.
Monitors should look up all of the source documents and
source data, and assess whether the coordinators carry out
these researches under the requirement of GCP with an
objective, rigorous, careful, and scientific attitude.
Monitoring provides clinicians and assessors with the
opportunity to discover problems early enough so that
they can be resolved. If data quality drops at the end of the
study, the results will have little value beyond providing a
cautionary example for future studies. Through the review
once a month at least, we can assist with corrective action
as needed. Points for attention during the monitoring
processes:
(1) Rechecking abnormal laboratory indicators as 
necessary as possible
When subjects enrolled, few indexes in laboratory check-
ing are unusual, such as the bradycardia in ECG test or low
leukocyte, but they did not have any correlated history or
pathological symptoms. The doctor should ask the sub-
jects to recheck these indicators in 3 days to confirm that
the performance for pathological or physiological abnor-
mality, and provide specialist consultation when neces-
sary. The patients will do the same examination after they
finish the treatment to clear whether acupuncture has
harmful effect.
(2) Inquiring treatment combination initiatively
During the period of therapy, patients might be affected
by their relatives or friends, go for other treatments other
than the prescribed medications. Most importantly, they
do not actively inform the clinicians about their addi-
tional medication. Therefore, during the treatment proc-
ess, it is necessary for the clinicians to enhance
communication with patients and often inquire the con-
comitant therapy comprehensively during the treatment
process.
(3) Supervising the qualified researchers in trials
During the implementation of clinical trials, some senior
postgraduate students will graduate sooner or later, so
every successor who will take part in the research should
pass the relevant training and examinations, in the hope
that they will master basic knowledge of GCP and com-
pletely control the implementation of research processes,
and qualify themselves for the trials.
Monitors' responsibilities are not only the clinical inspec-
tion, but facilitating collaboration among study coordina-
tors and sponsors.
1) During the audit schedule, we try to know the practical
difficulties and opinions in clinical centers through infor-
mal discussions, and we make efforts to resolve such dif-
ficulties, if necessary, through the sponsor to coordinate.
2) We can find out the problems in each unit existing in
the course of implementation through consulting the sub-
centers monitoring reports, and propose the solutions
other coordinators gained as reference.
3) The large sample, multi-center clinical trials have cer-
tain characteristics: Firstly, it has high-quality require-
ments in inclusion criteria. Secondly, the treating course
and follow-up period is relatively long. Thirdly, the mis-
sion is arduous, and clinicians have to pay much attention
to details. The investigators tend to get tired and volatile,
and this downside leads to a negative effect towards the
quality when the clinicians face the difficulties. The mon-
itors should encourage them, give them timely informa-
tion regarding the progress of the project, and let them be
aware of the importance and necessity of their work. The
monitors can pave the way for enhancing the coordina-
tion's exchange experience, for making good play of the
trial.
In summary, the quality assurance is very important in
acupuncture clinical research. Supplementing and
improving the existed guidelines for quality monitoring
will ensure that large multi-centre acupuncture clinical tri-
als will be considered as valid and scientifically stringent
as pharmaceutical clinical trials. It will also develop aca-
demic excellence and further promote the international
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